Top news of the week: 12.10.2022.
Nektar and PureTech merger talks called off
PureTech's discussions with Nektar over a possible merger are over for now, but don't rule out a deal just yet
Biopharma Soars to the Computational Clouds
Customized tools for collaborating in the clouds allow scientists to take back their time.
Nektar And PureTech Merger Talks Terminated
<p>The UK’s PureTech and US biotech Nektar have ended discussions about a potential merger which analysts did not see coming, but a deal could still happen and other companies may also make ...
For Swedish professor and his tiny biotech, Alzheimer’s drug means vindication and a fortune
If lecanemab reaches Wall Street estimates of $8 billion in annual sales, it could mean several hundred million dollars per year to an obscure Swedish biotech.
Andera Bullish About Prospects For Europe's Biotechs
The France-based firm has assembled a strong syndicate for its sixth generation of 'BioDiscovery' funds, consolidating its position as one of the leading players in life sciences venture ...
Bone Therapeutics’ development partner walks out on cell therapy deal, after lifeline merger delayed
There’s further drama at troubled Belgian biotech Bone Therapeutics SA, but its CEO told BioWorld that its partner’s decision to return rights to cell therapy platform Allob is a blessing ...
Merck touts positive results on key drug from $11.5 billion Acceleron merger
The results for a drug to treat pulmonary arterial hypertension is considered one of the most important pipeline readouts for Merck this year.
StockWatch: Despite Approval in ALS, Amylyx Sees No Price Surge
Amylyx shares have yo-yoed, rather than surged, since the company and the FDA announced the approval of Relyvrio™ (sodium phenylbutyrate and taurursodiol) to treat amyotrophic lateral ...